Home > Insider Trading > Filing (0001140361-17-047649)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1358762	Reata Pharmaceuticals Inc	RETA	Pharmaceutical Preparations (2834)	113651945

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1402856	Jr Kent R Mcgaughy	C/O Cpmg, Inc. 2000 Mckinney Ave, Ste 2125 Dallas TX 75201		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2017-12-26	12,000	$26.06	2,880,323	No	4	P	Indirect	See Footnote
Class A Common Stock	Acquisiton	2017-12-27	15,000	$25.83	2,895,323	No	4	P	Indirect	See Footnote
Class A Common Stock	Acquisiton	2017-12-28	200	$26.10	2,895,523	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	4,591	Indirect	By Lagos Trust
Class A Common Stock	280	Indirect	By Traweek Children's Trust
Class A Common Stock	2,739	Indirect	See footnote
Class A Common Stock	25,004	Direct

Footnotes

These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc.
The Reporting Person is trustee of Lagos Trust.
The Reporting Person is trustee of Traweek Children's Trust.
These shares of Class A common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC.
The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This price reflects the weighted average purchase price for open-market purchases on December 26, 2017, within a $1.00 range. The actual prices for these transactions range from $25.72 to $26.14 inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
This price reflects the weighted average purchase price for open-market purchases on December 27, 2017, within a $1.00 range. The actual prices for these transactions range from $25.595 to $26.00 inclusive.